Quantcast

Latest Clinical trial Stories

2014-08-21 08:28:33

ENGLEWOOD, Colo., Aug. 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a delay in the data analysis of the STEP Study due to the discovery by the independent Clinical Research Organization (CRO) that the study drug (both Ampion(TM) and the placebo) were, during shipment to the clinical sites, exposed to lower temperatures than permitted by the drug specifications. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Michael Macaluso, Ampio's...

2014-08-21 08:28:27

Mid and High Level Doses Demonstrate Statistically Significant Improvement in Cellulite Across All Endpoints; Nearly 70% of Mid and High Dose Patients Satisfied or Very Satisfied with Results CHESTERBROOK, Pa., Aug. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous...

2014-08-20 08:27:41

ENGLEWOOD, Colo., Aug. 20, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that in response to requests from patients and physicians, the company has performed an analysis of the available data from both portions of the study. On October 7, 2013, following an IDRC determination "that there was a treatment dosage (of Optina(TM)) that was demonstrating a potentially beneficial anatomic effect." The company initiated an open label extension study using the...

2014-08-19 23:13:32

With more than 50 years of combined experience, expert presenters Sherri Hubby and Brian Nugent will share insights that can be used to establish Risk Based Monitoring Plans, including triggers for return to 100% source data verification. Even better, they'll show attendees how to proactively identify and manage risks to trials with methods that can immediately be implemented and used. Falls Church, VA (PRWEB) August 19, 2014 Managing Risk for Clinical Trials: Incorporating Quality by...

2014-08-19 16:29:08

Funding To Increase Manufacturing Capacity for Ramp-Up of Programs BETHESDA, Md., Aug. 19, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the $17.5 million convertible note offering announced last Thursday, August 14, 2014, has closed. The three-year notes have a 5% interest rate and are convertible at $7.30 per share of common stock. The...

2014-08-19 08:29:50

VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 19, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m(2) has been opened at three clinical trial sites in the United...

2014-08-14 16:27:44

Company To Pursue Next Stage of Development REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira(®) in healthy subjects. The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined,...

2014-08-14 16:27:40

Signs Business Collaboration in South Korea with Wonik Corporation BRIDGEWATER, N.J., Aug. 14, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company...

2014-08-14 16:27:04

SANTA ROSA, Calif., Aug. 14, 2014 /PRNewswire/ -- Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fiscal first quarter 2015 ended June 30, 2014. Company Highlights -- Ruthigen Initiated Human Clinical Trials for RUT 58-60 in the U.S. In July 2014, Ruthigen began human clinical testing of RUT58-60 in its 21-day skin irritation trial. -- Ruthigen Completed the Skin Irritation Trial. In August 2014, Ruthigen completed the skin irritation...

2014-08-14 12:27:56

Convertible at $7.30 Per Share; Will Fund New Manufacturing Capacity in Europe BETHESDA, Md., Aug. 14, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio") today announced the pricing of $17.5 million aggregate principal amount of its unsecured convertible notes (the "Notes") in a private placement. The Notes are initially convertible at $7.30 per share, a 10% premium above the closing market price of $6.64 per share on August 13, 2014. NW Bio plans to...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related